Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

A systematic review and meta-analysis explored the relationship between androgen deprivation therapy and risk for heart failure in men with prostate cancer who were treated with ADT.

The current approach, which initiates medications and escalates to mechanical circulatory support, has not resulted in a ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

"These findings reinforce the use of dapagliflozin, 10 mg, or other SGLT2 inhibitors when the therapeutic goal is to reduce ...

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and ...

A higher risk of HF hospitalization was seen with dapagliflozin over empagliflozin, but one researcher urges caution.

The company shared interim results from an ongoing Phase II trial examining its recombinant antibody fusion protein.

It’s not yet time to abandon seated BP measurements, but taking a look at supine readings may provide enhanced risk ...

However, the benefits of beta-blockers in “stiff heart” heart failure are less clear. This condition, also known as heart ...

Popular medications approved for weight loss, diabetes, and heart disease may have health benefits beyond weight loss, and blood sugar control, but there are risks too.